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Ischemia and reperfusion injury (IRI) is the main etiology of
acute renal failure in native and transplanted kidneys. In the
transplantation field, immunosuppressive drugs may play
an additional role in acute graft dysfunction. Rapamycin
may impair renal regeneration post IRI. Heme oxygenase 1
(HO-1) is a protective gene with anti-inflammatory and
anti-apoptotic actions. We investigated whether HO-1
played a role in rapamycin-induced renal dysfunction in
an established model of IRI. Rapamycin (3 mg/kg) was
administered to mice before being subjected to 45 min of
ischemia. Animals subjected to IRI presented with impaired
renal function that peaked at 24 h (2.0570.23 mg/dl),
decreasing thereafter. Treatment with rapamycin caused
even more renal dysfunctions (2.3070.33 mg/dl), sustained
up to 120 h after reperfusion (1.5470.4 mg/dl), when
compared to the control (0.6370.09 mg/dl, Po0.05).
Rapamycin delayed tubular regeneration that was normally
higher in the control group at day 5 (68.5372.30 vs
43.6373.11%, Po0.05). HO-1 was markedly upregulated
after IRI and its expression was even enhanced by rapamycin
(1.32-fold). However, prior induction of HO-1 by cobalt
protoporphyrin improved the renal dysfunction imposed
by rapamycin, mostly at later time points. These results
demonstrated that rapamycin used in ischemic-injured
organs could also negatively affect post-transplantation
recovery. Modulation of HO-1 expression may represent
a feasible approach to limit rapamycin acute toxicity.
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The role of heme oxygenase 1 (HO-1) in rapamycin-induced
renal dysfunction after ischemia and reperfusion injury (IRI)
was studied. Long-term graft survival is mainly limited by
chronic allograft nephropathy.1 Its natural history tells us
that the acute injury is a factor in the early fibrotic damage
that ultimately leads to graft loss.2 IRI is an inflammatory
event that causes distinct degrees of cell dysfunction and
death, being the most important antigen-independent
negative factor associated with chronic allograft nephro-
pathy.3–8
New data support the concept that innate and adaptive
arms of the immune response participate in different
extensions in the pathogenesis of IRI.9–12 However, it is
worthy to emphasize that renal transplantation recipients are
exposed to additional detrimental factors besides interrup-
tion of blood flow. Donor antigen recognition and side effects
of immunosuppressive drugs might elicit additional insults
to a graft already dysfunctional.
Rapamycin is a macrocyclic lactone antibiotic with
immunosuppressive properties able to suppress IL-2 receptor
signaling via the mammalian target of rapamycins pathway.13
Clinical data have demonstrated its role in preventing acute
renal rejection, preservation of renal function in cyclospor-
ine-induced chronic nephrotoxicity patients, and in reducing
tumoral growth. However, some authors have reported side
effects with its use such as proteinuria and renal function
impairment, even in the native kidney.14–19 Lieberthal et al.19
have just demonstrated that rapamycin could be related to
renal tubular regeneration impairment after acute injury
through its ability to inhibit cell cycle and to induce
apoptosis.
It is well documented that the functional and histological
organ outcomes depend not only on the nature and intensity
of the aggressor, but also on the ability of the tissue to
respond in a protective way. Many molecules have intrinsic
cytoprotective properties that include anti-apoptotic, anti-
inflammatory, and anti-oxidant actions. HO-1 (EC 1.14.99.3)
comprises three distinct genes, that is, HO-1 (hmox1,
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P09601), HO-2 (hmox2, P30519) (reviewed in Camara
and Soares20), and HO-3 (hmox3, rat; O70453) that probably
does not encode a protein. HO-1 and HO-2 are the
rate-limiting enzymes in the catabolism of heme, a reaction
that yields equimolar amounts of biliverdin, Fe2þ ,
and carbon monoxide (CO). HO-2 is expressed in most
cell types whereas HO-1 is not. However, expression of
HO-1 is readily increased upon organ IRI becoming the rate-
limiting factor in the generation of biliverdin, Fe2þ and
CO.21–23 In this sense, HO-1 acts as a protective protein
expressed by endothelial cells that promote better graft
viability.
In this study, we investigated whether HO-1 may also play
a role in the additional renal function impairment imposed
by the immunosuppressive drugs, especially rapamycin. In an
established mouse model of acute renal failure, through vessel
pedicle occlusion, we observed that rapamycin worsened the
renal function and histology. However, upregulation of HO-1
was associated with the improvement of this dysfunction and
normalization of tissue morphology.
RESULTS
Rapamycin worsens acute renal function
IRI is a relevant negative factor in early and late renal graft
outcomes. Immunosuppressive drugs can also be a negative
factor by retarding graft recovery and sustaining the
extension phase of acute renal failure. We initially investi-
gated the impact of rapamycin treatment in a renal IRI
mouse model. The drug was administered 1 day before and
immediately before the surgery. IRI induced a severe renal
dysfunction assessed by serum creatinine levels that peaked
at 24 h (2.0570.23 mg/dl), decreasing thereafter (48 h:
1.0570.09 mg/dl; 120 h: 0.6370.09 mg/dl) (Figure 1). Inter-
estingly, rapamycin administration was associated with more
accentuated impairment in renal function that was signifi-
cantly higher at 48 (2.1770.6 mg/dl vs ischemic injured only
animals Po0.05) and 120 h (1.5470.4 mg/dl Po0.05) than
those observed in animals subjected only to IRI. Although,
we observed that 24 h after reperfusion, serum creatinine was
slightly higher (2.3070.33 mg/dl) than those observed in
animals subjected only to IRI, the difference did not reach a
statistical significance. It is noteworthy to say that the sham
and animals treated only with the drug had similar serum
creatinine levels compared with the normal animals
(0.5070.08 mg/dl) (Figure 1a).
However, in clinical setting organ transplant recipients are
under continuous use of immunosuppressive drugs. Then,
we questioned whether a daily treatment of rapamycin could
impair renal function else well. As seen in Figure 1b, the
exposure of rapamycin daily was associated with worse renal
function, compared to controls animals. Although the levels
were not statistically different from those seen in animals
just pre-treated with rapamycin (days 1 and 0), they were
considerably higher than controls (24 h: 2.1470.28 vs 2.057
0.23 mg/dl; 48 h; 2.6970.05 vs 1.0570.09 mg/dl; 120 h:
1.9170.11 vs 0.6370.09 mg/dl).
Morphometric analyses confirmed the functional data
described above. Indeed, the pretreatment with rapamycin
(days 1 and 0) was associated with higher levels of acute
tubular necrosis (ATN) in those animals subjected to IRI,
more important at day 1 after reperfusion (54.0772.56 vs
23.6871.95, respectively, Po0.05). The regeneration per-
centages observed in renal tubules were prominent in IRI
animals at 120 h after reperfusion, but severely decreased in
those animals treated with rapamycin (68.5372.30 vs
43.6373.11, respectively, Po0.05) (Figure 2).
Rapamycin induces early expression of HO-1 expression
HO-1 is a stress-induced enzyme related to cytoprotection
through heme degradation end-products. We were interested
in evaluating the expression of HO-1 after IRI by quantitative
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Figure 1 | Mean serum creatinine (s.d.) of animals subjected to IRI
(N¼ 9) or not (sham, N¼ 5), pre-treated with rapamycin (days 1
and 0), daily treated (N¼ 8) or not (N¼ 12). (a) Ischemic and
reperfusion injured animals pre-treated with rapamycin presented a
sustained renal dysfunction, more prominent at 48 (*Po0.05) and
120 h (*Po0.05), compared to IRI animals. Sham and rapamycin-
treated sham animals had similar levels of serum creatinine.
(b) Ischemic and reperfusion injured animals daily treated with
rapamycin presented a sustained renal dysfunction, more prominent
at 48 (*Po0.05) and 120 h (*Po0.05), compared to IRI animals.
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real-time polymerase chain reaction, and more importantly,
in those animals pre-treated with the immunosuppressive
drug. As previously demonstrated, HO-1 was markedly
upregulated after IRI, mainly 24 h (7.0870.58; 48 h,
3.3370.31) after reperfusion, decreasing at 120 h after
surgery (1.6870.29). This expression was significantly higher
than that observed in sham and normal animals (1.070.05).
The prior treatment with rapamycin resulted in 1.32-fold
increase in HO-1 mRNA expression at 24 h after reperfusion
(9.4071.83), and increased even higher 48 h later
(5.4870.28), although we observed only a statistical
significance in the later time point when compared to IRI
animals (P¼ 0.690 and P¼ 0.04, respectively). Conversely,
HO-1 expression was similar at 120 h after reperfusion
(0.7770.23) in rapamycin-treated animals when compared
to animals subjected only to IRI (1.6870.29, P40.05)
(Figure 3). Furthermore, rapamycin sham-treated animals
(24 h: 0.6370.02; 48 h: 1.0670.06; 120 h: 0.7770.06) did
not show a marked upregulation of HO-1 when compared to
sham animals (24 h: 0.370.09; 48 h: 0.6570.10; 120 h:
0.6170.04) (P40.500).
Cobalt protoporphyrin ameliorates rapamycin-induced
impairment in renal function after IRI
Upregulation of HO-1, before an insult, has been reported to
offer tissue protection in different animal injury models. We
addressed the question of how the induced expression of
HO-1 would be associated with amelioration of renal
function and tissue architecture in animals subjected to IRI,
but pre-treated with rapamycin. First, we observed that the
administration of cobalt protoporphyrin (COPPIX) resulted
in better renal function in those animals subjected to IRI, as
demonstrated by a significant decrease in serum creatinine
levels at early and regeneration time points. Indeed, at 24 and
120 h after reperfusion, serum creatinine had decreased to
0.7570.1 and 0.5670.06 mg/dl, respectively (Figure 4a).
When compared to animals just subjected to IRI, we
observed a significant difference only 24 h after reperfusion
(P¼ 0.011). The data obtained with sham and sham-treated
animals did not differ (Figure 4a).
Interestingly, COPPIX administration in animals sub-
jected to IRI and pre-treated with rapamycin was followed
by a noticeable improvement in renal function. Twenty-
four hours after reperfusion, serum creatinine levels reached
1.0370.3 mg/dl, significantly lower than those seen in
rapamycin-treated animals (Po0.01). Surprisingly, at
later time points where we had previously observed a
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Figure 2 | Morphometric analyses in animals subjected to IRI and
treated or not with rapamycin. (a) Mean percentages of ATN (s.d)
in animals subjected or not to IRI and pre-treated or not with
rapamycin. (b) Mean percentages of tubular regeneration (s.d) in
animals subjected or not to IRI and pre-treated or not with
rapamycin (N¼ 5–12). Morphometric analyses were performed
in 25 random fields in the outer medulla and compared at two
time points after reperfusion. Animals subjected to IRI and
pre-treated with rapamycin presented higher levels of ATN at
24 and 120 h (*Po0.05) and impaired regeneration at 120 h
(*Po0.05), compared to IRI animals.
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Figure 3 | HO-1 gene transcript analysis in normal animals and
in those subjected or not to IRI and pre-treated or not with
rapamycin (N¼ 5–12). HO-1 mRNA was markedly upregulated after
IRI; however, rapamycin pre-treatment induced an even higher
expression, significantly at 48 h after reperfusion (*Po0.05).
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negative impact of rapamycin therapy on renal function, the
induction of HO-1 was associated with normalization of
renal function (0.7070.15 mg/dl, P¼ 0.004) (Figure 4a).
HO-1 mRNA was markedly upregulated after COPPIX,
mainly at the later time points (24 h: 10.272.9; 120 h:
2.2470.7) (Figure 4b). More strikingly, COPPIX was able to
enhance HO-1, even when rapamycin was administered,
24 (4578.2) and 120 h (7.4373.2) after reperfusion,
coinciding with the observed improvement in renal function.
Additionally, we questioned whether the time of admin-
istration of COPPIX, and consequently the chemical induc-
tion of HO-1, would make the same benefit on renal function
in animals pre-treated or not with rapamycin. For that
purpose, animals were treated with COPPIX at the same time
of surgery (day 0) or 24 h after surgery (day þ 1), being pre-
treated or not with rapamycin (days 1 and 0). All animals
in these groups were killed 24 h after COPPIX administra-
tion. As seen in Figure 5a, late administration of COPPIX did
not restore renal function in animals subjected to IRI, pre-
treated or not with rapamycin. Interestingly, the late admini-
stration of COPPIX could nevertheless increase HO-1 mRNA
expression (Figure 5b).
On the other hand, we tested whether the blockade of
HO-1 expression by tin protoporphyrin (SnPPIX) would
interfere with rapamycin-induced renal dysfunction in those
animals subjected to IRI. As a matter of fact, SnPPIX
treatment exacerbated renal dysfunction in animals subjected
to IRI and in those that were pre-treated with rapamycin.
Specifically, SnPPIX administration blocked HO-1 upregula-
tion at 24 h (2.3870.56) after ischemia, even in those
animals pre-treated with rapamycin (3.0370.98). These
actions reflected in renal function, where we observed
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Figure 4 | Renal function and HO-1 mRNA expression in animals
treated with COPPIX before IRI. (a) Mean serum creatinine (s.d.)
levels of animals subjected or not to IRI, pre-treated with rapamycin,
COPPIX, both drugs or not (N¼ 5–12). COPPIX significantly decreased
renal dysfunction in animals just subjected to IRI (*vs IRI, P¼ 0.011),
and more strikingly, in those pre-treated with rapamycin (**vs
rapamycin-treated animals subjected to IRI, Po0.01). Interestingly,
at 120 h after reperfusion, COPPIX normalized renal function in
animals pre-treated with rapamycin and subjected to IRI (***vs
rapamycin-treated animals subjected to IRI, P¼ 0.004). (b) HO-1
mRNA expression after IRI. Rapamycin and COPPIX induced an
increase in HO-1 mRNA after IRI; however, when the two drugs
were administered together the effect was even higher (*vs IRI,
Po0.05). This effect was less evident at 120 h after surgery, but
still significant (**vs IRI, Po0.05).
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Figure 5 | Renal function and HO-1 mRNA expression in animals
subjected to IRI and treated with COPPIX at different time
points. (a) Mean serum creatinine (s.d.) levels of animals subjected
or not to IRI, pre-treated with rapamycin (days 1 and 0), and COPPIX
(at different time points, 1, 0, or þ 1) (N¼ 5–12). Animals were
killed 24 h after surgery (COPPIX at day 1) or after the COPPIX
administration (day 0 and day þ 1). COPPIX significantly decreased
renal dysfunction in animals just subjected to IRI, and in those
pre-treated with rapamycin, only when administered at day 1.
(b) HO-1 mRNA expression after IRI. Rapamycin and COPPIX
induced an increase in HO-1 mRNA after IRI. This effect was still
evident when COPPIX was administered late.
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increased levels of serum creatinine in those animals
(3.2770.41 and 2.9270.17 mg/dl, respectively) (Figure 6a
and b).
DISCUSSION
The early function of organs harvested from deceased donors
is substantially influenced by IRI, where preservation and
cold ischemia time play the major roles. After transplanta-
tion, the organ is still under insult from other factors such as
acute rejection and immunosuppressive drug toxicity. More-
over, minimization of immunosuppressive drugs is compro-
mised by the risk threatened by acute rejection.24 Rapamycin
presents today as an option for those patients under risk of
calcineurin inhibitor nephrotoxicity, while being able to
reduce acute rejection.25 Rapamycin has also been related to
anti-tumoral and anti-viral activities.26,27 However, recent
reports have suggested that it might prolong graft recovery
after ischemic injury through its ability to inhibit protein
synthesis, induce apoptosis that ultimately delay tubular
regeneration.19,28,29 Indeed, Fervenza et al.14 and colleagues
suggest that rapamycin might be nephrotoxic to native
kidneys by analyzing a population of glomerulopathies
patients. Pallet et al.29 showed that rapamycin inhibits
human epithelial cell cycles, by dramatically reducing p70S6
kinase phosphorylation and cyclin D3 expression. On the
other hand, there are some data demonstrating that, in fact,
rapamycin may preserve renal function in renal models of
acute renal failure and have benefits in bowel ischemic injury,
demonstrating the controversy about this subject that
appears to be dependent on animal models.30,31
In clinical settings, many authors have reported that
rapamycin delays early recovery of renal function post-
transplantation,15,18,32,33 having a controversial impact on
1-year graft survival. Simon and colleagues analyzed 8319
patients from the United States Renal Data System and
demonstrated that induction with rapamycin was indepen-
dently associated, through model-adjusted logistic regression
analyses, with delayed graft function. In their analyses,
rapamycin use had an adjusted odds ratio of 1.42 (95%
confidence interval: 1.07–1.90) of association with delayed
graft function.16
Furthermore, final organ function will largely depend
on its capacity to protect itself from these aggressors
via upregulation of molecules able to promote cytoprotec-
tion. Among those, HO-1 has gained a lot of attention
in recent years owing to its great ability to restore organ
function and tissue architecture after acute injury. Many
investigators have elegantly demonstrated its role in IRI
injury in organs such as the liver, kidney, and brain.34,35
Although the mechanism of action is still under debate,
there is a consensus that heme degradation end-products
are able to provide tissue protection as well.36–38 There are
little data on the HO-1 expression modulation by immuno-
suppressive drugs. Visner et al.39 showed that rapamycin
could actually increase HO-1 expression in an in vitro model
where lung endothelial and smooth cells were cultured in the
presence of platelet-derived growth factors. In addition, the
enhanced HO-1 expression was specific to rapamycin,
because no induction was observed in the presence of
cyclosporine and responsible for rapamycin anti-proliferative
capacity.39 Besides the possibility of HO-1 expression being
repressed by a GT(n) length promoter polymorphism, it has
not been excluded that immunosuppression might also
interfere with it.40
We first investigated whether rapamycin could indeed
aggravate an acute renal dysfunction in a mouse model of
IRI, corroborating with the experimental data and with the
clinical perception of an intrinsic nephrotoxicity of this drug.
Then, we investigated the potential of HO-1 expression as a
protective response to rapamycin acute nephrotoxicity and
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Figure 6 | Renal function and HO-1 mRNA expression in animals
treated with SnPPIX before IRI. (a) Mean serum creatinine (s.d.)
levels of animals subjected or not to IRI, pre-treated with rapamycin,
SnPPIX, both drugs or not (N¼ 5–12). SnPPIX significantly increased
renal dysfunction in animals just subjected to IRI (*vs IRI, P¼ 0.011),
and in those pre-treated with rapamycin (**vs IRI, Po0.01). (b) SnPPIX
treatment repressed HO-1 mRNA expression after IRI (*vs IRI,
Po0.01), even in those animals co-treated with rapamycin (N¼ 7)
(**vs rapamycin-treated animals subjected to IRI, Po0.01).
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reasoned that HO-1 upregulation could restore renal
function.
Initially, we observed animals pre-treated with rapamycin
sustained a worse renal function compared to animals just
subjected to IRI (Figure 1a). At 5 days after surgery, where we
do normally observe a cell regenerative response, rapamycin-
treated animals still had serum creatinine levels threefold
higher than matched controls. When we used a more clinical
relevant model, treating the animals daily with rapamycin, we
observed the same pattern. Histological analyses demon-
strated that ATN was significantly higher in animals exposed
to an immunosuppressive drug and regeneration was
inhibited at later time points (Figure 2a and b). We could
not demonstrate an acute nephrotoxicity in renal function
impairment as animals just treated with the drug presented
similar serum creatinine levels and we had no ATN to match
the controls thereafter.
One of the most important breakthroughs in IRI
pathogenesis came from pre-conditioning studies. Animals
subjected to a second ischemic injury are potentially protected
through upregulation of protective genes as HO-1, but also
through phosphorylation of survival kinases such as the axis
PI3-K-PDK-Akt-mTOR-MAPK-p70S6K in a cardiac model of
IRI.41–43 This axis is activated in response to ischemia and
reperfusion, where mediated protection came about through
the recruitment of downstream anti-apoptotic pathways, cell
growth control, and inactivation of proapoptotic proteins
such as Bad, Bax, and caspases.41,42 Many authors demon-
strated that pharmacological activation of these kinases at the
time of reperfusion, by administration of growth factors,
attributes to organ protection by limiting the apoptosis.44,45
One downstream member of this axis is p70S6K, which
phosphorylates members of the initiation complex of the
protein translational machinery. This pathway is especially
important in transplantation as it is inhibited by rapamycin.
Indeed, Kis et al.41 showed that rapamycin treatment inhibits
the benefits of pre-conditioning in a heart model of IRI by
preventing the phosphorylation of p70S6K. In clinical
settings, Loverre et al.28 demonstrated that Akt and p70S6K
were highly phosphorylated within tubular and infiltrating
cells in kidney graft biopsies from patients with delayed graft
function. Interestingly, p70S6K phosphorylation was almost
completely abolished in rapamycin-treated patients.28 We
believed that it might have also been the explanation for the
renal function impairment in our study, although we have not
addressed this issue specifically.
The link between these survival kinases and HO-1 has been
clarified in recent years. Briefly, it seems that after injury the
produced reactive oxygen species stimulate HO-1 expression
via phosphatidylinositol 30-kinase. Any pharmacology inter-
vention in this cascade leads to inhibition of HO-1
expression. More recent data demonstrated that activation
of Akt/PDK is also involved in the HO-1-inducible expres-
sion and that it can actually phosphorylate HO-1 at Serine
188. In this sense, we then investigated the role of HO-1 in
our model.
Initially, we observed that IRI induced an early and
vigorous expression of HO-1, which continued to be elevated
during the 5 days of observation (Figure 3). More interest-
ingly, the acute toxic effect of rapamycin treatment was also
accompanied by an even higher expression of HO-1.
Conversely from what we saw in animals just subjected to
IRI, where HO-1 expression decreases as time passed by,
rapamycin-treated animals continued with higher levels of
HO-1 up to 48 h after reperfusion, simultaneous to the
behavior of serum creatinine, demonstrating its additional
detrimental insult. In this sense, the HO-1 expression seen
here could be more related to rapamycin cytotoxicity, even
though we could not detect a rise in serum creatinine values
in rapamycin-treated only animals. Besides that, although,
mammalian target of rapamycin inhibition by rapamycin
leads to inactivation of p70S6 kinase, we believed that the
upstream axis is still preserved and able to upregulate HO-1
expression facing an injury. Conversely, the prior induction
of HO-1 can actually protect not only the organ from IRI,
but also the additional acute nephrotoxic effect of rapamycin,
probably by favoring an anti-inflammatory and anti-
apoptotic environment (Figure 4). Interestingly, if we delayed
the administration of COPPIX, we could not see the same
improvement in renal function (Figure 5a), although this
drugs could indeed increase HO-1 mRNA expression. We
believe that these results demonstrate the importance of
previous upregulation of HO-1 in order to have cytoprotec-
tion. The observed increment in HO-1 mRNA could be the
result of the chemically induced expression summed with the
stress-induced expression. Corroborating these results, the
repression of HO-1 exacerbated the dysfunction super-
imposed by rapamycin treatment (Figure 6). These results
are clinically relevant, as it is completely feasible to limit
future graft dysfunction by modulating HO-1 expression in
harvested organs during preservation time, especially those
that will be randomized to use mammalian target of
rapamycin inhibitors.
Rapamycin has been used in calcineurin-spared immuno-
suppressive situations in order to prevent the later side
effects; however, cumulative evidence shows that it also has
intrinsic renal toxicity. Its ability to limit tubular recovery
after ischemic insults could be partially overcome by
upregulation of protective genes such as HO-1.
MATERIALS AND METHODS
Animals
Isogenic male C57Bl/6 mice (H2-Ab), age 5–9 weeks (25–28 g), were
purchased from Animal Facilities Center from CEDEME at
Universidade Federal de Sa˜o Paulo. All animals were housed in
individual standard cages and had free access to water and food. All
procedures were previously reviewed and approved by the internal
Ethical Committee of the Institution.
IRI model
Surgery was performed as previously described.46 The mice were
briefly anesthetized with ketamine–xylazine (Agribrands do Brazil,
Sa˜o Paulo, Brazil). A midline incision was made and both renal
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pedicles were cross-clamped. During the procedure, animals were
kept well hydrated with saline and kept at a constant temperature
(B371C) through a heating pad device. Forty-five minutes later, the
microsurgical clamps were removed. The abdomen was closed in
two layers and the animals were placed in single cages, warmed by
indirect light until completely recovered from anesthesia. The model
is associated with a mortality of 10–15% mainly in the first 48 h after
reperfusion. The association of rapamycin increased the mortality to
22% in the first 48 h, although not significantly different from the
control.
Study design
Animals were assigned in the following groups: group 1 (n¼ 9),
animals submitted to IRI; group 2 (n¼ 9), animals submitted to IRI
and pre-treated with rapamycin (days 1 and 0); group 3 (n¼ 8),
animals submitted to IRI and daily treated with rapamycin; group 4
(n¼ 12), animals submitted to IRI and pre-treated with COPPIX
(day 1); group 5 (n¼ 7), animals submitted to IRI and pre-treated
with COPPIX (day 0); group 6 (n¼ 6), animals submitted to IRI
and pre-treated with COPPIX (day þ 1); group 7 (n¼ 11), animals
subjected to IRI and pre-treated with rapamycin (days 1 and 0)
and COPPIX (day 1); group 8 (n¼ 11), animals subjected to IRI
and pre-treated with rapamycin (days 1 and 0) and COPPIX (day
0); group 9 (n¼ 11), animals subjected to IRI and pre-treated with
rapamycin (days 1 and 0) and COPPIX (day þ 1); group 10
(n¼ 11), animals subjected to IRI and pre-treated with SnPPIX; and
group 11 (n¼ 7), animals pre-treated with rapamycin (days 1 and
0) and SnPPIX. Animals were killed at days 1, 2, and 5 after
reperfusion, except in groups 4 and 7, where the animals were killed
24 and 120 h after surgery, and in groups 5, 6, 8, 9, 10, and 11, where
the animals were killed 24 h after surgery. Additionally, animals were
subjected to the surgical procedure without renal vessels occlusion
(sham), pre-treated or not with all drugs, in combination or not
(n¼ 5).
Drugs
Rapamycin was given in a dose of 3 mg/kg,19 per gavage,
1 day before and at the day of IR (days 1 and 0), or daily until
the animal was killed. The drug (1 mg/ml) was dissolved in a
solution of 0.9% NaCl and ethanol (30:55:15). COPPIX and SnPPIX
were given intraperitoneally at 5 mg/kg and 30mm/kg, 1 day before
the surgery.
Renal function outcome
Blood was collected for serum creatinine measurements and kidneys
were harvested for histological and mRNA analyses at the end
points. Serum creatinine was measured in duplicate by the Jaffe´
modified method (Roche, Mannheim, Germany). The extension of
tubular necrosis (ATN) morphology and patterns of regeneration in
the outer medulla was examined by blinded morphometric
assessment using a computer-assisted image system with an
Olympus BX40F-3 microscope (Olympus Optical Company, Tokyo,
Japan) and the software program KS300 program (Zeiss, Go¨ttingen,
Germany). The results were expressed as a ratio of the injured area
related to total area (14 58 467 mm2). Twenty-five random fields were
counted at an original magnification  835, almost covering all
outer medulla, corresponding to an area of 3.64 61 675mm2, for each
animal, per lamina. For morphometric analyses, ATN and
regeneration were analyzed at 24 and 120 h after reperfusion.
Tubular necrosis pattern included: loss of cytoplasmatic and nuclear
membranes integrity, loss of brush border, vacuolization of tubular
epithelial cells, and presence of intratubular debris. Tubular
regeneration or repair was characterized by attenuated epithelium
enclosing dilated lumens filled with proteinaceous fluid or granular
material. Mitotic figures may be present or tubules were lined by
basophilic epithelium, with basophilic cytoplasm and hyperchro-
matic nuclei or vesicular nuclei with prominent nucleoli.
Gene profiles
Kidney samples were quickly frozen in liquid nitrogen. Total RNA
was isolated from kidney tissue using TRIzol Reagent (Invitrogen,
Carlsbad, CA, USA) methodology and RNA concentration was
determined by spectrophotometer readings at absorbance 260 nm.
First-strand cDNAs were synthesized using the MML-V reverse
transcriptase (Promega, Madison, WI, USA). Reverse transcription-
polymerase chain reaction was performed using the SYBR Green
real-time polymerase chain reaction assay (Applied Biosystem,
Foster City, CA, USA). Sequences of primers used were: HO-1
(sense) 50-TCA GTC CCA AAC GTC GCG GT-30 and (anti-sense)
50-GCT GTG CAG GTG TTG AGC C-30 and hypoxanthine guanine
phosphoribosyltransferase (sense) 50-CTC ATG GAC TGA TTA TGG
ACA GGA C-30 and (anti-sense) 50-GCA GGT CAG CAA AGA ACT
TAT AGC C-30. Cycling conditions were as follows: 10 min at 951C
followed by 45 cycles of 20 s at 951C, 20 s at 53.51C, and 20 s at 721C.
Analysis used Sequence Detection Software 1.9 (SDS). The mRNA
expression was normalized to hypoxanthine guanine phosphoribo-
syltransferase abundance. Subsequently, all data were expressed
relative to the expression of the matched controls (sham).
Statistics
All data were described as mean7s.d. Parametric and non-
parametric tests were performed when the sample distribution were
considered normal or not. Different evolutions among the groups
were compared using analysis of variance followed by Tukey’s or
Dunn’s test for individual comparisons among groups. The null
hypothesis was rejected when Po0.05. All statistical analyses were
performed with aid of Stata Statistical Software 5.0 (Stata
Corporation, College Station, TX, USA).
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